Trial Profile
A Multicenter, Open-label Study Evaluating the Safety and Efficacy of a New Protease Inhibitor (Darunavir) With Fuzeon® (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-class Treatment-experienced Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Enfuvirtide (Primary) ; Darunavir; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms BLQ
- Sponsors Roche
- 15 Nov 2006 Status change
- 02 Jun 2006 New trial record.